Skip to main content
. 2024 Mar 1;15:1896. doi: 10.1038/s41467-024-45784-0

Table 2.

Adverse drug reactions in participants receiving LY3056480 for SNHL

System Organ Class (term) Event LY3056480
N = 59
n (%)
Cardiac disorders Sinus bradycardia 1 (2%)
Ear and labyrinth disorders Ear discomfort 14 (24%)
Ear pain 13 (22%)
Hypoacusis 16 (27%)
Dysacusis 1 (2%)
Tinnitus 27 (46%)
Ear congestion 12 (20%)
External ear pain 1 (2%)
Ear pruritus 1 (2%)
Vertigo 1 (2%)
Gastrointestinal disorders Nausea 2 (3%)
Hypoaesthesia oral 3 (5%)
Dry mouth 1 (2%)
Tongue dry 1 (2%)
Abdominal discomfort 2 (3%)
Oral pruritus 2 (3%)
Noninfective gingivitis 1 (2%)
General disorders and administration site conditions Injection site pain 49 (83%)
Injection site pruritus 3 (5%)
Feeling abnormal 1 (2%)
Pain 2 (3%)
Injection site discomfort 1 (2%)
Injury, poisoning and procedural complications Procedural pain 15 (25%)
Procedural dizziness 7 (12%)
Post procedural discomfort 1 (2%)
Investigations Acoustic stimulation tests abnormal 1 (2%)
Blood pressure increased 1 (2%)
Musculoskeletal and connective tissue disorders Pain in jaw 6 (10%)
Arthralgia 1 (2%)
Nervous system disorders Headache 5 (8%)
Dysgeusia 4 (7%)
Dizziness 13 (22%)
Dizziness postural 1 (2%)
Hypoaesthesia 1 (2%)
Respiratory, thoracic and mediastinal disorders Dry throat 1 (2%)
Oropharyngeal pain 5 (8%)
Throat irritation 2 (3%)
Skin Rash 1 (2%)
Acne 1 (2%)